Collaborative physical activity program for newly-diagnosed cancer patients
Impact of a Collaborative Program of Customized, Adaptive and Supervised Physical Activity on Adherence, Fitness, Quality of Life and Resilience of Newly-diagnosed Cancer Patients
NA · University Hospital, Toulouse · NCT05723471
This study is testing whether a special exercise program can help newly-diagnosed cancer patients feel better and stick to their workouts compared to regular exercise plans.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 350 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Toulouse (other) |
| Locations | 2 sites (Nancy, France and 1 other locations) |
| Trial ID | NCT05723471 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of a customized collaborative exercise program compared to standard exercise prescriptions for patients who have recently been diagnosed with cancer. It is a multicenter, randomized, open-label trial that aims to assess long-term adherence to physical activity and its impact on quality of life, treatment tolerance, and survival rates. Participants will be randomly assigned to either the adaptive physical activity group or the control group, with the goal of improving their overall well-being during cancer treatment.
Who should consider this trial
Good fit: Ideal candidates are newly-diagnosed cancer patients who can begin a physical activity program within the first year of their diagnosis and have a performance status between 0 to 2.
Not a fit: Patients with uncontrolled cardiovascular disease, severe peripheral neuropathy, or other serious health conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly enhance the quality of life and treatment outcomes for newly-diagnosed cancer patients.
How similar studies have performed: Previous studies have shown that adaptive physical activity can improve quality of life and treatment tolerance in cancer patients, indicating a promising approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * newly-diagnosed cancer patient * able to start a program of physical activity within the first year follow diagnosis * performance status between 0 to 2 Exclusion Criteria: * uncontrolled cardiovascular disease * peripheral neuropathy grade 3-4 with risk of falling * bone metastasis with risk of bone fracture * platelets \<100X109/L * hemoglobin \<8g/dL * patient under legal protection
Where this trial is running
Nancy, France and 1 other locations
- CHRU de Nancy — Nancy, France, France (RECRUITING)
- Stéphanie MOTTON — Toulouse, France, France (RECRUITING)
Study contacts
- Principal investigator: Stéphanie MOTTON, MD — University Hospital, Toulouse
- Study coordinator: Laura BOGDANOVITCH
- Email: bogdanovitch.l@chu-toulouse.fr
- Phone: 0561778437
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cancer, Adaptative physical activity, Quality of Life